Kenvue (KVUE) Earnings: Q3 Fiscal 2026 Results

The quarter ended September 27, 2026 and Kenvue published the results on October 30, 2026. Revenue and diluted EPS are shown against Q3 fiscal 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Kenvue reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted diluted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Kimberly-Clark agreed on November 2, 2025 to acquire Kenvue for 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash per Kenvue share. Because of the pending transaction, Kenvue gave no forward-looking guidance and held no conference call for this quarter.
• Kenvue's fiscal quarters end on a Sunday: Q3 fiscal 2026 ended September 27, 2026 and Q3 fiscal 2025 ended September 28, 2025.

Source: Kenvue Q3 2026 results, October 30, 2026. Also in the Form 10-Q for the quarter ended September 27, 2026. Figures as reported; checked against the release on November 10, 2026.

How Kenvue splits revenue in its own release, under its own labels, for Q3 fiscal 2026 against Q3 fiscal 2025. Indented lines are parts of the line above them.

• Kenvue's Self Care revenue was $1.7 billion in Q3 fiscal 2026, up 6% from $1.6 billion in Q3 fiscal 2025, 43% of total revenue.
• Kenvue's Skin Health and Beauty revenue was $1.0 billion in Q3 fiscal 2026, flat on $1.0 billion in Q3 fiscal 2025, 27% of total revenue.
• Kenvue's Essential Health revenue was $1.2 billion in Q3 fiscal 2026, up 2% from $1.2 billion in Q3 fiscal 2025, 31% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's earnings release.

We do not hold a confirmed date for Kenvue's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 fiscal 2026 (this page), reported Oct 30, 2026

Kenvue sells consumer health products in three segments. In Q3 fiscal 2026 Self Care, which covers cough, cold and allergy, pain care, digestive health, smoking cessation and eye care, brought in $1,656 million of the $3,886 million total. Essential Health (oral care, baby care, women's health and wound care) added $1,191 million and Skin Health and Beauty (face, body, hair and sun) $1,039 million. (Kenvue Q3 2026 release, Oct 30, 2026; Kenvue Form 10-Q, Q3 2026, Oct 30, 2026)

Kenvue's net sales rose 3.2%, made up of organic sales growth of 2.9% and a foreign currency benefit of 0.3%. Organic growth split into volume growth of 1.6% and value realization, Kenvue's term for price and mix, of 1.3%. (Kenvue Q3 2026 release, Oct 30, 2026)

Self Care grew fastest, with net sales up 5.9% and organic sales up 5.4% on a volume increase of 3.4%. Kenvue credited Pain Care and Cough and Cold in Asia Pacific, where the prior year had trade inventory depletion and flu incidences rose, plus Nicorette in smoking cessation. Skin Health and Beauty net sales rose 0.1% but organic sales fell 0.5%, with volume down 1.7% on distribution losses and promotion timing in the U.S. and retailer price negotiations in Europe. (Kenvue Q3 2026 release, Oct 30, 2026; Kenvue Form 10-Q, Q3 2026, Oct 30, 2026)

Kenvue depends on a few large retailers. One customer accounted for approximately 12% of total net sales in fiscal 2025, and the top 10 customers for approximately 41%. North America produced $7,259 million of fiscal 2025 net sales of $15,124 million, including $6,460 million in the U.S., followed by Europe, Middle East, and Africa at $3,721 million, Asia-Pacific at $2,775 million and Latin America at $1,369 million. (Kenvue Form 10-K, fiscal 2025, Feb 20, 2026)

Kenvue's GAAP diluted EPS was $0.22 in Q3 fiscal 2026 and its adjusted diluted EPS was $0.29. The gap is $138 million of net adjustments that lift net income from $430 million to $568 million, led by $64 million of intangible asset amortization, $33 million of restructuring expenses, $28 million of costs tied to the pending Kimberly-Clark transaction and $8 million of operating model optimization initiatives. (Kenvue Q3 2026 release, Oct 30, 2026)

Taxes held back GAAP EPS growth. Kenvue's effective tax rate was 29.4%, against 24.3% a year earlier, which it attributed largely to smaller favorable discrete return-to-provision adjustments. The adjusted effective tax rate was 24.7%, against 24.0%. (Kenvue Q3 2026 release, Oct 30, 2026)

Kenvue's diluted share count was 1,926 million, against 1,923 million a year earlier. Under the merger agreement Kenvue may not repurchase its shares without Kimberly-Clark's consent, and it has repurchased none since signing. Its equity statement records cash dividends of $0.42 per share, or $807 million, in the quarter, which covers the $0.21 dividend paid in August and a second $0.21 dividend declared on September 10, 2026. (Kenvue Q3 2026 release, Oct 30, 2026; Kenvue Form 10-Q, Q3 2026, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Kenvue stated in its Q3 fiscal 2026 release that, due to the pending transaction with Kimberly-Clark, it will not be providing forward-looking guidance, and it did not host a conference call. The only forward figure in the release is that the 2026 Restructuring Initiative is expected to bring pre-tax restructuring expenses and other charges of approximately $250 million in fiscal 2026. (Kenvue Q3 2026 release, Oct 30, 2026)

Under the merger agreement, each Kenvue share is to receive 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash, leaving current Kenvue shareholders with approximately 46% of the combined company. Shareholders of both companies approved the deal on January 29, 2026 and the Hart-Scott-Rodino waiting period expired on February 4, 2026; the 10-Q says the deal remains subject to other customary closing conditions. (Kenvue Form 10-Q, Q3 2026, Oct 30, 2026)

A consensus figure is the average of the models published by the analysts who cover Kenvue, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Kenvue's own release and filings put weight on for Q3 fiscal 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning KVUE is on is KVUE a buy or a sell?, what analysts expect next is on the KVUE forecast, and what the company does is on the Kenvue (KVUE) stock page.

Every number on this page can be traced to a document Kenvue published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.